153 related articles for article (PubMed ID: 14652227)
1. A hot flash on tamoxifen metabolism.
Goetz MP; Loprinzi CL
J Natl Cancer Inst; 2003 Dec; 95(23):1734-5. PubMed ID: 14652227
[No Abstract] [Full Text] [Related]
2. Tamoxifen pharmacogenetics moves closer to reality.
Garber K
J Natl Cancer Inst; 2005 Mar; 97(6):412-3. PubMed ID: 15770000
[No Abstract] [Full Text] [Related]
3. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Henry NL; Stearns V; Flockhart DA; Hayes DF; Riba M
Am J Psychiatry; 2008 Oct; 165(10):1251-5. PubMed ID: 18829880
[No Abstract] [Full Text] [Related]
4. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ponzone R; Biglia N; Sismondi P
J Natl Cancer Inst; 2004 Jun; 96(11):883-4; author reply 884-5. PubMed ID: 15173274
[No Abstract] [Full Text] [Related]
5. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
6. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Holzman D
J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
[No Abstract] [Full Text] [Related]
8. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ratliff B; Dietze EC; Bean GR; Moore C; Wanko S; Seewaldt VL
J Natl Cancer Inst; 2004 Jun; 96(11):883; author reply 884-5. PubMed ID: 15173275
[No Abstract] [Full Text] [Related]
9. Understanding CYP2D6 and its role in tamoxifen metabolism.
Smith EC
Oncol Nurs Forum; 2013 Nov; 40(6):547-8. PubMed ID: 24161632
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
[TBL] [Abstract][Full Text] [Related]
12. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Desmarais JE; Looper KJ
J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
[TBL] [Abstract][Full Text] [Related]
13. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.
Bonanni B; Macis D; Maisonneuve P; Johansson HA; Gucciardo G; Oliviero P; Travaglini R; Muraca MG; Rotmensz N; Veronesi U; Decensi AU
J Clin Oncol; 2006 Aug; 24(22):3708-9; author reply 3709. PubMed ID: 16877740
[No Abstract] [Full Text] [Related]
14. Response to "Understanding CYP2D6 and its role in tamoxifen metabolism".
Kaplan M; Mahon SM
Oncol Nurs Forum; 2014 Jan; 41(1):12. PubMed ID: 24368234
[No Abstract] [Full Text] [Related]
15. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Henry NL; Rae JM; Li L; Azzouz F; Skaar TC; Desta Z; Sikora MJ; Philips S; Nguyen AT; Storniolo AM; Hayes DF; Flockhart DA; Stearns V;
Breast Cancer Res Treat; 2009 Oct; 117(3):571-5. PubMed ID: 19153830
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.
Baxter SD; Teft WA; Choi YH; Winquist E; Kim RB
Breast Cancer Res Treat; 2014 Jun; 145(2):419-28. PubMed ID: 24744093
[TBL] [Abstract][Full Text] [Related]
17. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
18. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Gjerde J; Hauglid M; Breilid H; Lundgren S; Varhaug JE; Kisanga ER; Mellgren G; Steen VM; Lien EA
Ann Oncol; 2008 Jan; 19(1):56-61. PubMed ID: 17947222
[TBL] [Abstract][Full Text] [Related]
19. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
[No Abstract] [Full Text] [Related]
20. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Chlebowski RT; Col N
J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
[No Abstract] [Full Text] [Related]
[Next] [New Search]